Merck receives FDA approval for new formulation of Isentress As we continue to …
This vaccine makes up about 15% -20% of the Merck anti-infectives division revenues (reflected with Nasonex), which in turn represents about 23% to the value of the company, according to our estimates. This means that there can be 5% of the Merck-value …
Read more at NASDAQ